Progress and trends in complement therapeutics

Advances in Experimental Medicine and Biology

Volumn 734, Issue , 2013, Pages 1-22

  Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; ARC 1905; BACTERIAL PROTEIN; BACTERIAL VACCINE; BCX 1470; CD59 ANTIGEN; CHEMOTAXIS INHIBITOR; CHEMOTAXIS INHIBITOR PROTEIN OF STAPHYLOCOCCUS AUREUS; COBROTOXIN; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; COMPSTATIN; ECULIZUMAB; MIROCOCEPT; NOX D19; OPSONIN; ORNITHODOROS MOUBATA COMPLEMENT INHIBITOR; PROPERDIN; PROTEINASE INHIBITOR; SMALL INTERFERING RNA; TA 106; UNCLASSIFIED DRUG; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN; ANTIINFLAMMATORY AGENT; NEW DRUG;

ANGIONEUROTIC EDEMA; AUTOIMMUNE DISEASE; BIODIVERSITY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION RISK; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MYASTHENIA GRAVIS; NONHUMAN; PERCEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; SEPSIS; SIGNAL TRANSDUCTION; SKIN EDEMA; TREATMENT RESPONSE; ACUTE DISEASE; BIOTECHNOLOGY; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); COMPLEMENT DISORDER; COMPLEMENT SYSTEM; DISEASE MODEL; DISEASES; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; HEALTH; MOLECULAR SIZE; PROTEIN INTERACTION; RARE DISEASE; TREND STUDY;

EID: 84934440020     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4118-2_1     Document Type: Conference Paper

References (167)

1. Ahmad M, Pyaram K, Mullick J, Sahu A (2007) Viral complement regulators: the expert mimicking swindlers. Indian J Biochem Biophys 44(5):331-3433
2. Alcorlo M, Martinez-Barricarte R, Fernandez FJ, Rodriguez-Gallego C, Round A, Vega MC et al (2011) Unique structure of iC3b resolved at a resolution of 24 A by 3D-electron microscopy. Proc Natl Acad Sci USA 108(32):13236-132400
3. Alexion (2011) Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS). Alexion Pharmaceuticals Press Releasee
4. Alfinito F, Ruggiero G, Sica M, Udhayachandran A, Rubino V, Pepa RD et al (2011) Eculizumab treatment modifies the immune profile of PNH patients. Immunobiology 217(7):698-7033
5. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B et al (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185(9):5628-56366
6. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR et al (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29(2):95-1122
7. Arlaud GJ, Barlow PN, Gaboriaud C, Gros P, Narayana SV (2007) Deciphering complement mechanisms: the contributions of structural biology. Mol Immunol 44(16):3809-38222
8. Asgari E, Zhou W, Sacks S (2010) Complement in organ transplantation. Curr Opin Organ Transplant 15(4):486-4911
9. Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL et al (2009) Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 183(9):5928-59377
10. Banz Y, Rieben R (2012) Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med 44(3):205-2177
11. Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P et al (2007) Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovasc Res 76(3):482-4933
12. Barratt-Due A, Thorgersen EB, Lindstad JK, Pharo A, Lissina O, Lambris JD et al (2011) Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J Immunol 187(9):4913-49199
13. Beinrohr L, Dobo J, Zavodszky P, Gal P (2008) C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated in flammation. Trends Mol Med 14(12):511-5211
14. Berger J (1974) Complement deposition in the kidney. Adv Nephrol Necker Hosp 4:37-488
15. Blonder J, Issaq HJ, Veenstra TD (2011) Proteomic biomarker discovery: it's more than just mass spectrometry. Electrophoresis 32(13):1541-15488
16. Bora NS, Jha P, Lyzogubov VV, Kaliappan S, Liu J, Tytarenko RG et al (2010) Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice. J Biol Chem 285(44):33826-338333
17. Bosmann M, Ward PA (2012) Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol 946:147-1599
18. Brodbeck RM, Cortright DN, Kieltyka AP, Yu J, Baltazar CO, Buck ME et al (2008) Identi fication and characterization of NDT 9513727 [N, N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanam ine], a novel, orally bioavailable C5a receptor inverse agonist. J Pharmacol Exp Ther 327(3):898-9099
19. Brown KM, Sacks SH, Sheerin NS (2007) Mechanisms of disease: the complement system in renal injury - new ways of looking at an old foe. Nat Clin Pract Nephrol 3(5):277-2866
20. Carroll MV, Sim RB (2011) Complement in health and disease. Adv Drug Deliv Rev 63(12):965-9755
21. Cashman SM, Ramo K, Kumar-Singh R (2011) A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One 6(4):e190788
22. Chavakis T, Preissner KT, Herrmann M (2007) The anti-inflammatory activities of Staphylococcus aureus . Trends Immunol 28(9):408-4188
23. Chen Song S, Zhong S, Xiang Y, Li JH, Guo H, Wang WY et al (2011) Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 11(10):2057-20666
24. Chen H, Ricklin D, Hammel M, Garcia BL, McWhorter WJ, Sfyroera G et al (2010) Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc Natl Acad Sci USA 107(41):17621-176266
25. Chi ZL, Yoshida T, Lambris JD, Iwata T (2010) Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol 703:127-1355
26. Christiansen D, Brekke OL, Stenvik J, Lambris JD, Espevik T, Mollnes TE (2012) Differential effect of inhibiting MD-2 and CD14 on LPS-versus whole E. coli bacteria-induced cytokine responses in human blood. Adv Exp Med Biol 946:237-2511
27. Davis AE 3rd, Lu F, Mejia P (2010) C1inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 104(5):886-8933
28. Degn SE, Jensenius JC, Thiel S (2011) Disease-causing mutations in genes of the complement system. Am J Hum Gen 88(6):689-7055
29. Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R (2008) FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 13(9):993-10000
30. Ekdahl KN, Lambris JD, Elwing H, Ricklin D, Nilsson PH, Teramura Y et al (2011) Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv Drug Deliv Rev 63(12):1042-10500
31. Engstrom G, Hedblad B, Janzon L, Lindgarde F (2007) Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil 14(3):392-3977
32. Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM et al (2009) Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol 183(2):1375-13833
33. Fonseca MI, Chu SH, Berci AM, Benoit ME, Peters DG, Kimura Y et al (2011) Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroin flammation 8(1):44
34. Forneris F, Ricklin D, Wu J, Tzekou A, Wallace RS, Lambris JD et al (2010) Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330(6012):1816-18200
35. Fraser DA, Harris CL, Williams AS, Mizuno M, Gallagher S, Smith RA et al (2003) Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem 278(49):48921-489277
36. Fridkis-Hareli M, Storek M, Mazsaroff I, Risitano AM, Lundberg AS, Horvath CJ et al (2011) Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathwaymediated diseases. Blood 118(17):4705-47133
37. Fritzinger DC, Dean R, Meschter C, Wong K, Halter R, Borlak J et al (2010) Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration. Adv Exp Med Biol 703:151-1622
38. Fujita E, Farkas I, Campbell W, Baranyi L, Okada H, Okada N (2004) Inactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5a. J Immunol 172(10):6382-63877
39. Fujiwara I, Nakajima H, Akioka K, Matsuda T, Oka T (1997) Soluble complement receptor type 1 and antithrombin-III combination therapy prolongs xenograft survival: the role of thrombin and prostacyclin in hyperacute rejection. Transplant Proc 29(1-2):935-9377
40. Garlatti V, Chouquet A, Lunardi T, Vives R, Paidassi H, Lortat-Jacob H et al (2010) Cutting edge: C1q binds deoxyribose and heparan sulfate through neighboring sites of its recognition domain. J Immunol 185(2):808-8122
41. Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X et al (2011) rILYd4, a human CD59 inhibitor, enhances complementdependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 17(21):6702-67111
42. Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S et al (2010) Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets 10(8):922-9311
43. Ghebremariam YT, Engelbrecht G, Tyler M, Lotz Z, Govender D, Kotwal GJ et al (2010) Vaccinia virus complement control protein (VCP) improves kidney structure and function following ischemia/reperfusion injury in rats. J Surg Res 159(2):747-7544
44. Gibson J, Hakobyan S, Cree AJ, Collins A, Harris CL, Ennis S et al (2012) Variation in complement component C11 inhibitor in age-related macular degeneration. Immunobiology 217(2):251-2555
45. Gingras AR, Girija UV, Keeble AH, Panchal R, Mitchell DA, Moody PC et al (2011) Structural basis of mannanbinding lectin recognition by its associated serine protease MASP-1: implications for complement activation. Structure 19(11):1635-16433
46. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12):e150044
47. Gombos T, Forhecz Z, Pozsonyi Z, Szeplaki G, Kunde J, Fust G et al (2012) Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure. Clin Res Cardiol. doi:10.1007/s00392-012-0432-66
48. Gompels MM, Lock RJ (2011) Cinryze (C1-inhibitor) for the treatment of hereditary angioedema. Expert Rev Clin Immunol 7(5):569-5733
49. Gustafsson E, Forsberg C, Haraldsson K, Lindman S, Ljung L, Furebring C (2009) Puri fication of truncated and mutated chemotaxis inhibitory protein of Staphylococcus aureus - an anti-inflammatory protein. Protein Expr Purif 63(2):95-1011
50. Hadders MA, Bubeck D, Roversi P, Hakobyan S, Forneris F, Morgan BP et al (2012) Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep 1:1-88
51. Halili MA, Ruiz-Gomez G, Le GT, Abbenante G, Fairlie DP (2009) Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation. Biochemistry 48(35):8466-84722
52. Hamilton G, Evans KL, Macintyre DJ, Deary IJ, Dominiczak A, Smith BH et al (2012) Alzheimer's disease risk factor complement receptor 1 is associated with depression. Neurosci Lett 510(1):6-99
53. Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, Brown WL et al (2010) Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet 19(1):209-2155
54. Hepburn NJ, Williams AS, Nunn MA, Chamberlain-Banoub JC, Hamer J, Morgan BP et al (2007) In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata . J Biol Chem 282(11):8292-82999
55. Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP et al (2011) Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 108(21):8761-87666
56. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S (2008) A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 181(11):8068-80766
57. Igonin AA, Protsenko DN, Galstyan GM, Vlasenko AV, Khachatryan NN, Nekhaev IV et al (2011) C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med 40:770-7777
58. Janssen BJ, Huizinga EG, Raaijmakers HC, Roos A, Daha MR, Nilsson-Ekdahl K et al (2005) Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437(7058):505-5111
59. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P (2006) Structure of C3b reveals conformational changes that underlie complement activity. Nature 444(7116):213-2166
60. Kajander T, Lehtinen MJ, Hyvarinen S, Bhattacharjee A, Leung E, Isenman DE et al (2011) Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci USA 108(7):2897-29022
61. Kato M, Morozumi K, Takeuchi O, Oikawa T, Koyama K, Usami T et al (2003) Complement fragment C4d deposition in peritubular capillaries in acute humoral rejection after ABO blood group-incompatible human kidney transplantation. Transplantation 75(5):663-6655
62. Keating GM (2009) Human C1-esterase inhibitor concentrate (Berinert). BioDrugs 23(6):399-4066
63. Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C et al (2011) CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res 109(11): 1290-13011
64. Kirschfink M, Mollnes TE (2001) C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2(7):1073-10833
65. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J (2009) The role of the anaphylatoxins in health and disease. Mol Immunol 46(14):2753-27666
66. Kocsis A, Kekesi KA, Szasz R, Vegh BM, Balczer J, Dobo J et al (2010) Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation. J Immunol 185(7):4169-41788
67. Kohl J (2006) Drug evaluation: the C5a receptor antagonist PMX-53. Curr Opin Mol Ther 8(6):529-5388
68. Kollessery G, Nordgren TM, Mittal AK, Joshi SS, Sanderson SD (2011) Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model. Vaccine 29(35):5904-59100
69. Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, Mitroulis I et al (2010) Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116(4):631-6399
70. Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, Keeney TR et al (2011) From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One 6(10):e263322
71. Kulkarni AP, Govender DA, Kotwal GJ, Kellaway LA (2011) Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer's disease. Curr Alzheimer Res 8(1):95-1133
72. Laarman A, Milder F, van Strijp J, Rooijakkers S (2010) Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications. J Mol Med (Berlin) 88(2):115-1200
73. Lachmann PJ, Smith RA (2009) Taking complement to the clinic - has the time fi nally come? Scand J Immunol 69(6):471-4788
74. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al (2009) Genome-wide association study identi fies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41(10):1094-10999
75. Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion by human pathogens. Nat Rev Microbiol 6(2):132-1422
76. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M et al. (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364(26):2561-25633
77. Laursen L (2011) E. coli crisis opens door for Alexion drug trial. Nat Biotechnol 29(8):6711
78. Laursen NS, Gordon N, Hermans S, Lorenz N, Jackson N, Wines B et al (2010) Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus . Proc Natl Acad Sci USA 107(8):3681-36866
79. Laursen NS, Andersen KR, Braren I, Spillner E, Sottrup-Jensen L, Andersen GR (2011) Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J 30(3):606-6166
80. Lazar HL, Keilani T, Fitzgerald CA, Shapira OM, Hunter CT, Shemin RJ et al (2007) Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation 116(11 Suppl):I83-I888
81. Lewis AG, Kohl G, Ma Q, Devarajan P, Kohl J (2008) Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol 153(1):117-1266
82. Li JS, Jaggers J, Anderson PA (2006) The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev Cardiovasc Ther 4(5):649-6544
83. Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B et al (2005) Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H Deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 45(2):415-4211
84. Luzzatto L, Risitano AM, Notaro R (2010) Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica 95(4):523-5266
85. Lynch AM, Gibbs RS, Murphy JR, Byers T, Neville MC, Giclas PC et al (2008) Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol 199(4):354 e1-88
86. Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM (2011) Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol 117(1):75-833
87. Markiewski MM, Lambris JD (2009) Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 30(6):286-2922
88. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C et al (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9(11):1225-12355
89. Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y et al (2005) The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett 100(2):139-1455
90. Monk PN, Scola AM, Madala P, Fairlie DP (2007) Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 152(4):429-4488
91. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP et al (2011) Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol 18(4):463-4700
92. Mosca T, Menezes MC, Dionigi PC, Stirbulov R, Forte WC (2011) C3 and C4 complement system components as biomarkers in the intermittent atopic asthma diagnosis. J Pediatr (Rio de Janeiro) 87(6):512-5166
93. Mullard A (2012) Protein-protein interaction inhibitors get into the groove. Nat Rev Drug Discov 11(3):173-1755
94. Nagar B, Jones RG, Diefenbach RJ, Isenman DE, Rini JM (1998) X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 280(5367):1277-12811
95. Nilsson B, Nilsson UR, Karlsson-Parra A, Sjolin-Forsberg G, Hallgren R (1994) Reconstitution of the alternative pathway of complement by plasma infusions given to a patient with an SLE-like syndrome associated with a hereditary C3 dysfunction. Ann Rheum Dis 53(10):691-6944
96. Nilsson B, Korsgren O, Lambris JD, Ekdahl KN (2010) Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol 31(1):32-388
97. Nunn MA, Sharma A, Paesen GC, Adamson S, Lissina O, Willis AC et al (2005) Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata . J Immunol 174(4):2084-20911
98. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA et al (2009) Eculizumab for atypical hemolyticuremic syndrome. N Engl J Med 360(5):542-5444
99. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD (2012) Interactions between coagulation and complement - their role in in flammation. Semin Immunopathol 34(1):151-1655
100. Otto M, Hawlisch H, Monk PN, Muller M, Klos A, Karp CL et al (2004) C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J Biol Chem 279(1):142-1511
101. Palikhe A, Sinisalo J, Seppanen M, Haario H, Meri S, Valtonen V et al (2007) Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 99(7):890-8955
102. Parker CJ (2012) Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 19(3):141-1488
103. Patel H, Smith RA, Sacks SH, Zhou W (2006) Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 17(4):1102-11111
104. Perkins SJ, Gilbert HE, Aslam M, Hannan J, Holers VM, Goodship TH (2002) Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem Soc Trans 30(Pt 6): 996-10011
105. Perkins SJ, Gilbert HE, Aslam M, Hannan J, Holers VM, Goodship TH (2002) Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem Soc Trans 30(Pt 6):996-10011
106. Proitsi P, Lupton MK, Dudbridge F, Tsolaki M, Hamilton G, Daniilidou M et al (2012) Alzheimer's disease and agerelated macular degeneration have different genetic models for complement gene variation. Neurobiol Aging 33(8):1843.e9-1843.e177
107. Qu H, Ricklin D, Bai H, Chen H, Reis ES, Maciejewski M, Tzekou A, DeAngelis RA, Resuello RRG, Lupu F, Barlow PN, Lambris JD (2012) New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology (in press). doi:10.1016/j.imbio.2012.06.0033
108. Qu H, Ricklin D, Lambris JD (2009) Recent developments in low molecular weight complement inhibitors. Mol Immunol 47(2-3):185-1955
109. Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ et al (2011) Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol 48(4):481-4899
110. Ramos-Casals M, Campoamor MT, Chamorro A, Salvador G, Segura S, Botero JC et al (2004) Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 13(10):777-7833
111. Recknagel S, Bindl R, Kurz J, Wehner T, Schoengraf P, Ehrnthaller C et al (2012) C5aR-antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing. J Orthop Res 30(4):581-5866
112. Reis SE, Falcao DA, Isaac L (2006) Clinical aspects and molecular basis of primary de ficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol 63(3):155-1688
113. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM (2009) Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 50(12):5818-58277
114. Ricklin D, Lambris JD (2007a) Complement-targeted therapeutics. Nat Biotechnol 25(11):1265-12755
115. Ricklin D, Lambris JD (2007b) Exploring the complement interaction network using surface plasmon resonance. Adv Exp Med Biol 598:260-2788
116. Ricklin D, Lambris JD (2008) Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 632:273-2922
117. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11(9):785-7977
118. Risitano AM, Perna F, Selleri C (2011) Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Mini Rev Med Chem 11(6):528-5355
119. Rodriguez de Cordoba S, Harris CL, Morgan BP, Llorca O (2011) Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochim Biophys Acta 1812(1):12-222
120. Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K et al (2010) A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol 703:137-1499
121. Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM (2012) Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther. doi:10.1089/jop.2011.02122
122. Rooijakkers SH, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A et al (2009) Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol 10(7):721-7277
123. Roth A, Hock C, Konik A, Christoph S, Duhrsen U (2011) Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int J Hematol 93(6):704-7144
124. Roversi P, Lissina O, Johnson S, Ahmat N, Paesen GC, Ploss K et al (2007) The structure of OMCI, a novel lipocalin inhibitor of the complement system. J Mol Biol 369(3):784-7933
125. Ruiz-Gomez G, Lim J, Halili MA, Le GT, Madala PK, Abbenante G et al (2009) Structure-activity relationships for substrate-based inhibitors of human complement factor B. J Med Chem 52(19):6042-60522
126. Sacks SH, Zhou W (2012) The role of complement in the early response to transplantation. Nat Rev Immunol 12(6):431-4422
127. Sahu A, Kay BK, Lambris JD (1996) Inhibition of human complement by a C3-binding peptide isolated from a phagedisplayed random peptide library. J Immunol 157(2):884-8911
128. Sample I (2010) Mirococept could double life of transplant organs. The Guardian 2010. http://www.guardian.co.uk/science/2010/sep/15/mirococept- transplant-organs
129. Sanchez-Carbayo M (2011) Antibody microarrays as tools for biomarker discovery. Methods Mol Biol 785:159-1822
130. Schmid RA, Hillinger S, Hamacher J, Stammberger U (2001) TP20 is superior to TP10 in reducing ischemia/reperfusion injury in rat lung grafts. Transplant Proc 33(1-2):948-9499
131. Schmidt CQ, Bai H, Risitano AM, Barlow PN, Ricklin D, Lambris JD (2012) Rational engineering of a novel complement regulator affords double targeting of host cells and controls innate immunity in disease condition (submitted))
132. Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Borncke F et al (2008) Systemic complement activation in age-related macular degeneration. PLoS One 3(7):e25933
133. Schuster MC, Chen H, Lambris JD (2007) Hydrogen/deuterium exchange mass spectrometry: potential for investigating innate immunity proteins. Adv Exp Med Biol 598:407-4177
134. Schuster MC, Ricklin D, Papp K, Molnar KS, Coales SJ, Hamuro Y et al (2008) Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. Mol Immunol 45(11):3142-31511
135. Serkova NJ, Renner B, Larsen BA, Stoldt CR, Hasebroock KM, Bradshaw-Pierce EL et al (2010) Renal in flammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 255(2):517-5266
136. Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM et al (2010) Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol 404(4):697-7100
137. Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P et al (2010) Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116(6):1002-10100
138. Sirmaci A, Walsh T, Akay H, Spiliopoulos M, Sakalar YB, Hasanefendioglu-Bayrak A et al (2010) MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory fi ndings of Carnevale, Malpuech, OSA, and Michels syndromes. Am J Hum Genet 87(5):679-6866
139. Skattum L, Martensson U, Sjoholm AG (1997) Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical fi ndings and the coincidence of C3 NeF type II with anti-C1q autoantibodies. J Intern Med 242(6):455-4644
140. Skattum L, van Deuren M, van der Poll T, Truedsson L (2011) Complement Deficiency states and associated infections. Mol Immunol 48(14):1643-16555
141. Smith RA (2002) Targeting anticomplement agents. Biochem Soc Trans 30(Pt 6):1037-10411
142. Smith GP, Smith RA (2001) Membrane-targeted complement inhibitors. Mol Immunol 38(2-3):249-2555
143. Sokolov A, Hellerud BC, Lambris JD, Johannessen EA, Mollnes TE (2011) Activation of polymorphonuclear leukocytes by candidate biomaterials for an implantable glucose sensor. J Diabetes Sci Technol 5(6):1490-14988
144. Souza DG, Esser D, Bradford R, Vieira AT, Teixeira MM (2005) APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 145(8):1027-10344
145. Spitzer D, Unsinger J, Bessler M, Atkinson JP (2004) ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 40(13):911-9199
146. Spitzer D, Unsinger J, Mao D, Wu X, Molina H, Atkinson JP (2005) In vivo correction of complement regulatory protein Deficiency with an inhibitor targeting the red blood cell membrane. J Immunol 175(11):7763-77700
147. Szalai AJ, Digerness SB, Agrawal A, Kearney JF, Bucy RP, Niwas S et al (2000) The Arthus reaction in rodents: species-specific requirement of complement. J Immunol 164(1):463-4688
148. Thorgersen EB, Ludviksen JK, Lambris JD, Sfyroera G, Nielsen EW, Mollnes TE (2010) Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity. Innate Immun 16(4):254-2644
149. Tillou X, Poirier N, Le Bas-Bernardet S, Hervouet J, Minault D, Renaudin K et al (2010) Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 78(2):152-1599
150. Tokodai K, Goto M, Inagaki A, Nakanishi W, Ogawa N, Satoh K et al (2010) Attenuation of cross-talk between the complement and coagulation cascades by C5a blockade improves early outcomes after intraportal islet transplantation. Transplantation 90(12):1358-13655
151. Torreira E, Tortajada A, Montes T, Rodriguez de Cordoba S, Llorca O (2009) 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc Natl Acad Sci USA 106(3):882-8877
152. Tourangeau LM, Zuraw BL (2011) The new era of C1-esterase inhibitor Deficiency therapy. Curr Allergy Asthma Rep 11(5):345-3511
153. Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD (2011) Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological fi ndings. Pediatr Nephrol 26(11):2085-20888
154. van den Elsen JM, Isenman DE (2011) A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science 332(6029):608-6111
155. van der Pals J, Koul S, Andersson P, Gotberg M, Ubachs JF, Kanski M et al (2010) Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc Disord 10:455
156. Veerhuis R, Nielsen HM, Tenner AJ (2011) Complement in the brain. Mol Immunol 48(14):1592-16033
157. Vogel CW, Fritzinger DC (2010) Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 56(7):1198-12222
158. Waters AM, Licht C (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 26(1):41-577
159. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450(7172):1001-10099
160. Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ et al (2006) Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444(7116):217-2200
161. Woodruff TM, Nandakumar KS, Tedesco F (2011) Inhibiting the C5-C5a receptor axis. Mol Immunol 48(14): 1631-16422
162. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P (2009) Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 10(7):728-7333
163. Wu YQ, Qu H, Sfyroera G, Tzekou A, Kay BK, Nilsson B et al (2011) Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol 186(7):4269-42777
164. Yehoshua Z, Rosenfeld PJ, Albini TA (2011) Current clinical trials in dry AMD and the de finition of appropriate clinical outcome measures. Semin Ophthalmol 26(3):167-1800
165. Zeerleder S (2011) C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost 37(4):362-3744
166. Zilow G, Sturm JA, Rother U, Kirschfink M (1990) Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 79(2):151-1577
167. Zipfel PF, Lauer NL, Ricklin D, Heinen SH, Dahse HMD, Tzekou A et al (2011) The new chimeric alternative complement inhibitor COMP-CFH15-20 protects surfaces from complement-mediated damage (conference abstract). Mol Immunol 48(14):17133